Rheumatology Unit, University of Verona, Policlinico Borgo Roma, Verona.
Reumatismo. 2020 Jul 23;72(2):71-74. doi: 10.4081/reumatismo.2020.1267.
In this retrospective study, we intended to investigate the baseline fracture risk profile in patients who started treatment with different anti-osteoporotic medications. We analyzed retrospectively the fracture risk calculated with DeFRA, a validated FRAX derived tool, in women who started an anti-osteoporotic treatment from 2010 to 2017. We analyzed baseline data of 12,024 post-menopausal women aged over 50 years. Teriparatide initiators had a baseline 10-year risk of major osteoporotic fracture of 82.1% with a Standard Deviation (SD) of 66.5%. Denosumab initiators and zoledronic acid initiators had a greater 10-year baseline risk of fracture (54.3%, SD 46.5% and 47.0%, SD 42.0 respectively) than patients initiated on alendronate (24.9%, SD 34.6%) and patients initiated on risedronate (23.9%, SD 24.1%). Using DeFRA, a FRAX™ derived tool, we showed significantly different fracture risk profiles in women who were started on various therapeutic agents for the treatment of osteoporosis in routine clinical practice.
在这项回顾性研究中，我们旨在研究开始使用不同抗骨质疏松药物治疗的患者的基线骨折风险特征。我们回顾性地分析了 2010 年至 2017 年期间开始接受抗骨质疏松治疗的女性使用 DeFRA（一种经过验证的 FRAX 衍生工具）计算的骨折风险。我们分析了 12024 名年龄在 50 岁以上的绝经后女性的基线数据。特立帕肽的起始者的 10 年主要骨质疏松性骨折风险为 82.1%，标准差为 66.5%。地舒单抗的起始者和唑来膦酸的起始者的骨折基线风险更高（54.3%，标准差为 46.5%和 47.0%，标准差为 42.0%），高于阿仑膦酸钠（24.9%，标准差为 34.6%）和利塞膦酸钠（23.9%，标准差为 24.1%）的起始者。使用 DeFRA（一种 FRAX ™衍生工具），我们在常规临床实践中开始使用各种治疗药物治疗骨质疏松症的女性中显示出明显不同的骨折风险特征。
